Iron Deficiency Guidelines: WHO and India's AMB Protocol

These iron deficiency guidelines matter for a very unglamorous reason: NFHS-4 to NFHS-5 data showed almost no improvement in anaemia prevalence across age groups despite a decade of programmatic investment, which is why the diagnostic and dosing protocol itself keeps getting revised. This piece covers what the current thresholds actually say, who AMB targets, and where oral iron stops being enough.

What haemoglobin level actually defines anaemia?

WHO's 2024 guideline sets haemoglobin cutoffs by age and physiological state rather than one number for everyone. Non-pregnant women 15 and older are anaemic below 12.0 g/dL; men 15 and older below 13.0 g/dL.

Pregnant women are anaemic below 11.0 g/dL in the first and third trimester, and below 10.5 g/dL in the second trimester under the revised 2024 figures. Children aged 6–23 months now use a 10.5 g/dL cutoff, down from the earlier 11.0 g/dL threshold. This is the first change to these reference values since WHO's original 1968 numbers.

How is iron deficiency itself diagnosed, separate from anaemia?

Anaemia and iron deficiency are not the same diagnosis, and guidelines increasingly treat serum ferritin as the primary marker for iron status specifically. WHO's ferritin guideline recommends a cutoff around 15 ng/mL to define depleted iron stores in otherwise healthy individuals, though clinical guidance for populations with inflammation commonly uses higher cutoffs, up to 70 ng/mL, since ferritin rises as an acute-phase reactant.

A patient can be iron deficient with a normal haemoglobin, and a patient can be anaemic from causes other than iron. This is why a ferritin or transferrin saturation test, not haemoglobin alone, is the guideline-recommended way to confirm iron deficiency before starting therapy.

Who does India's Anemia Mukt Bharat programme actually target?

Anemia Mukt Bharat, run under the National Health Mission, targets six life-stage groups: children 6–59 months, children 5–9 years, adolescents 10–19 years, pregnant women, lactating women, and women of reproductive age. This is often summarised as the programme's 6x6x6 strategy: six target groups, six interventions, six institutional mechanisms.

The programme's central intervention is supervised iron-folic acid prophylaxis delivered through anganwadi centres and schools, alongside deworming, testing, and behaviour-change communication on iron-rich diets. AMB set a target of reducing anaemia prevalence by 3 percentage points a year toward the Global World Health Assembly 2025 goal of a 50% reduction among women of reproductive age.

Why has anaemia prevalence barely moved despite the programme?

NFHS-5 data compared against NFHS-4 showed little to no improvement in anaemia prevalence across the age groups AMB targets, despite a decade of national iron-folic acid rollout. A comprehensive review of the programme's iron prophylaxis component points to gaps in supervised dosing compliance and testing coverage, not the underlying diagnostic thresholds, as the more likely explanation.

This stagnation is the reason current guidance increasingly separates screening from blanket prophylaxis. Confirming iron deficiency with ferritin testing before treatment, rather than treating on haemoglobin trend alone, is now the more defensible clinical approach even within a mass public-health programme.

When does a guideline point toward intravenous iron instead of oral therapy?

Oral iron remains first-line across current guidelines, but the RAPIDIRON trial, a three-arm randomised controlled trial in pregnant Indian women, directly compared oral iron against single-dose intravenous iron for iron deficiency anaemia in pregnancy. The trial was designed specifically because oral absorption is unreliable in a meaningful share of pregnant patients and correction needs to happen before delivery.

Guidelines generally reserve intravenous iron for patients with poor oral tolerance, malabsorption, inflammatory bowel disease, chronic kidney disease, or anaemia severe enough that the correction timeline oral therapy allows is clinically unacceptable. This is a prescriber decision made case by case. It is not a substitution a patient or pharmacist makes independently, and the RAPIDIRON design itself shows why the comparison needed a randomised trial rather than informal practice.

What does this mean for a hospital's iron and IFA stocking decisions?

A hospital or clinic running antenatal, adolescent or paediatric OPD services sees IFA tablets and, increasingly, intravenous iron formulations as recurring, predictable-volume prescriptions tied directly to national screening protocols. When the in-house pharmacy doesn't reliably stock the correct oral IFA formulation or the IV iron product a prescriber has moved to, that prescription leaves for an outside chemist.

Reliable in-house stocking against a programme-driven demand pattern like AMB is a straightforward operational problem, and Medyzen's managed hospital pharmacy services piece covers how that stocking model is built around exactly this kind of predictable prescribing pattern. The prescription leakage piece covers what a hospital loses, in continuity and in revenue, every time that walk-out happens, and the inventory management guide covers the reorder discipline a programme-driven drug list like this one needs.

Sources

1. 1WHO guideline on haemoglobin cutoffs to define anaemia in individuals and populations — World Health Organization, 2024
2. 2WHO guideline on the use of ferritin concentrations to assess iron status — World Health Organization
3. 3Intensified National Iron Plus Initiative — Anemia Mukt Bharat Operational Guidelines — National Health Mission, Ministry of Health and Family Welfare
4. 4National Iron Plus Initiative: Current status and future strategy — Indian Journal of Medical Research
5. 5RAPIDIRON: Reducing Anaemia in Pregnancy in India — National Institutes of Health, PMC

This article is for informational purposes and is not a substitute for professional medical advice. Diagnostic thresholds and programme details are drawn from cited WHO and government sources and are subject to periodic revision. Consult a treating physician for individual case management.